Sulbactam-Durlobactam for Treating Patients with Acinetobacter baumannii Infections: Do MICs Matter?

Characterizing A. baumannii isolates revealed no influence of sul-dur MICs on microbiologic treatment outcomes.

Management of carbapenem-resistant Acinetobacter baumannii (CRAB) is a priority in the antimicrobial drug pipeline. The beta-lactam–beta-lactamase inhibitor combination sulbactam-durlobactam (sul-dur) was FDA-approved in 2023 for treating CRAB based on favorable results in the ATTACK trial, in which imipenem plus either sul-dur or colistin was assessed (NEJM JW Infect Dis Sep 11 2023; multiple citations). In a detailed analysis of baseline isolates from the ATTACK trial, researchers correlated sul-dur minimum inhibitory concentrations (MICs) with microbiologic outcomes and evaluated molecular influences on sul-dur resistance.

Among 175 isolates, 96% were carbapenem resistant, 95% were sulbactam resistant, and 5% were resistant to sul-dur (MI…

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases